stockrow
Saturday 7 November 2026
Export ERNA’s income statement to Excel — free account
Ernexa Therapeutics Inc.
ERNA Healthcare Biotechnology
Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023.
- Revenue
- −94.1%
- EPS
- +77.7%
- Free cash flow
- −64.1%
Quarter to June 2026, against a year earlier
1.88
0.05
+2.73%
Follow ERNA
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
87.78% | (687.80%) | (2,514.66%) | (321.22%) | |
| (264.31%) | (253.99%) | (146.19%) | (176.62%) | ||
ROIC |
(1,185.59%) | (1,126.57%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,383.27%) | (12,368.42%) | (172.08%) | (403.22%) | |
Average Days of Receivables |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(29.50) | (28.03) | (9.16) | (7.50) | |
Free Cash Flow |
(9.70) | (7.07) | (7.25) | (8.88) | |
Capital Expenditures |
(0.29) | (0.06) | (0.04) | (0.04) | |
| Other line items | |||||
Cash ROIC |
(146.65%) | (165.06%) | (45.24%) | (107.90%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.01) | (0.01) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.51 | 0.50 | 0.63 | 0.72 | |
Depreciation/Fixed assets |
36.66 | 2.80 | 26.41 | 28.21 | |
Capex/Depreciation |
(0.09) | (0.21) | (0.02) | (0.02) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(28.61) | (27.81) | (9.11) | (7.47) | |
Capex per Share |
(0.88) | (0.22) | (0.05) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026